drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Allogeneic, gene-edited T-cell therapy engineered with a reverse, universal CAR displaying an extracellular peptide epitope; given as a single IV infusion to enable dose-tunable engagement of CD123+ AML cells when bridged by R-TM123.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, gene-edited T cells expressing a reverse, universal CAR that displays an extracellular peptide epitope. Anti-leukemia activity is adapter-dependent: the bispecific protein R-TM123 binds both the RevCAR epitope and CD123 on tumor cells, bridging the engineered T cells to CD123+ blasts to trigger CAR signaling and cytotoxic killing with dose-tunable control.
drug_name
Allo-RevCAR01-T
nct_id_drug_ref
NCT05949125